Each year, a staggering 13 million adults across the country grapple with the weight of major depression. Among those seeking care, nearly 40 percent find no respite or full recovery through conventional antidepressant medications. For those battling the relentless darkness of depression, ketamine, first used as an anesthesia medicine in the 1960s, represents a powerful tool in the fight against Major Depressive Disorder and treatment-resistant depression.
Spravato, approved by the FDA in 2019, offers new hope for individuals with Major Depressive Disorder that is treatment-resistant or includes suicidal thoughts. More easily delivered than IV ketamine, Spravato is an intranasal spray that harnesses the power of esketamine, a potent ketamine derivative. Provided in a comfortable, supervised and supportive in-office setting, Spravato offers rapid relief from depression symptoms.
You arrive, settle into a quiet treatment room and self-administer the nasal spray under the supervision of our team. There are no needles and no infusion.
You then rest in the room for about two hours while we monitor you. Most patients read, listen to music or simply relax. Because esketamine can cause temporary drowsiness or dizziness, you will need someone to drive you home.
Spravato may be a fit if you:
Our team specializes in prior authorizations and benefit verification. Request an appointment and we will check your coverage before your first visit.
Request an appointment
Tell us a little about yourself and the clinic you would like to visit. We verify insurance for you, and most plans need no referral.
We will review your message and be in touch soon.
Please do not include medical details here. We will follow up by phone.
Refer a patient, a friend, or make the decision for yourself. Contact us today to set up a free consultation with an Intake Coordinator.